Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Verily Life Sciences LLC

verily.com

Latest From Verily Life Sciences LLC

Exec Chat: ResMed's CEO Mick Farrell Outlines 2025 Strategy For 250 Million Users

ResMed's CEO Mick Farrell outlined the company's 2025 strategy: double-digit growth, drive up its user base to 250 million people and becoming the leading digital health company in both sleep apnea and chronic obstructive pulmonary (COPD) disease. Medtech Insight sat down with Farrell at ResMed's San Diego headquarters to learn more.

Exec Chat Digital Health

Verily And iRhythm Agree To Collaborate On Atrial Fibrillation

Verily Life Sciences and iRhythm Technologies have agreed to co-develop technology for screening, diagnosing and managing patients with atrial fibrillation, combining iRhythm’s artificial intelligence system for diagnosing arrhythmias with Verily’s health data analytics technology.

Deals Artificial Intelligence

One Small Step For US FDA, But Maybe A Giant Leap For SaMDs

In a midyear update from the FDA, regulators say a retrospective review of companies in its pre-cert pilot program has concluded that evaluating a company for excellence markers could be sufficient to let software as a medical device (SaMD) onto the market. However, at least one critic says the update doesn’t answer some of the most critical questions about whether the program meets the agency's own requirements and if it creates unfair advantages for certain companies.

Regulation Digital Health

Medicxi Closes €400m Medicxi III Biotech Fund In 6 Weeks

European life sciences investment firm Medicxi shows institutional investor appetite for life sciences venture capital is still strong as it secures €400m in an over-subscribed offering.

Commercial Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
  • In Vitro Diagnostics
    • Biosensors
    • Glucose Testing
  • Medical Devices
    • Implantable Devices
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Metabolic Disorders
  • Ophthalmic
  • Alias(es)
  • Google Life Sciences
  • Google life sciences spin-off
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Verily Life Sciences LLC
  • Senior Management
  • Andy Conrad, CEO
    Duncan Welstead, CFO
    Jessica Mega, MD, Chief Medical & Scientific Officer
    Ashraf Hanna, MD, PhD, COO
    Brian Otis, PhD, CTO
  • Contact Info
  • Verily Life Sciences LLC
    ,
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register